

NEUTRAL

| | |
|-------------------|-------|
| Price | Rs561 |
| Target Price | - |
| Investment Period | - |

Stock Info

| | |
|--------------------|----------------|
| Sector | Pharmaceutical |
| Market Cap (Rs cr) | 20,931 |
| Beta | 0.57 |
| 52 WK High / Low | 593/300 |
| Avg Daily Volume | 3,75,491 |
| Face Value (Rs) | 5 |

| | |
|------------|--------|
| BSE Sensex | 15,185 |
| Nifty | 4,524 |

| | |
|----------------|---------|
| BSE Code | 500359 |
| NSE Code | RANBAXY |
| Reuters Code | RANB.BO |
| Bloomberg Code | RBXY IN |

Shareholding Pattern (%)

| | |
|---------------------|------|
| Promoters | 34.8 |
| MF/Banks/Indian FIs | 23.3 |
| FII/ NRIs/ OCBs | 21.0 |
| Indian Public | 20.9 |

| Abs. | 3m | 1yr | 3yr |
|-------------|-------|------|-------|
| Sensex (%) | (5.8) | 7.8 | 123.9 |
| Ranbaxy (%) | 23.7 | 51.5 | 4.8 |

Sarabjit Kour Nangra

Tel: 2022 – 4040 3800 Ext: 343
 e-mail: sarabjit@angeltrade.com

Akshat Vyas

Tel: 2022 – 4040 3800 Ext: 329
 e-mail: akshat.vyas@angeltrade.com

Ranbaxy stake sale to Daiichi Sankyo

- Contours of the Deal:** In one of its kind deal in the corporate space, Daiichi Sankyo Co., the second largest pharmaceutical company in Japan, has taken a stake in India's largest pharmaceutical company, Ranbaxy Laboratories. This is also the first of the instances of a Generic and Innovator company coming together.

According to the agreement, Daiichi has taken full 34.8% stake held by the promoters of Ranbaxy at Rs737 per share. With this, Daiichi would make an open offer for upto 20% additional stake in Ranbaxy. Apart from this Daiichi would be issued preferential shares and warrants of 46,258,063 and 23,834,333 respectively, at Rs737/share. The warrants can be exercised by Daiichi within 6-18 months after the issue. With this, assuming conversion of the FCCB, fully diluted Equity of Ranbaxy would go up from 38.2cr to 48.6cr, a dilution of 27%.

On a fully diluted basis, the deal values Ranbaxy at \$8.5bn. At current levels, Ranbaxy would be valued at 4x EV/Sales and 24.7x EV/EBITDA on CY2009E Earnings. The stake buyout is expected to be completed by March 2009 and on completion, Ranbaxy would become a subsidiary of Daiichi Sankyo. Further, Ranbaxy's NCE business unit, which was supposed to be demerged into a different entity, will continue to remain under its fold and will not be demerged as of now.

- What does the Deal entail for Ranbaxy?** Daiichi Sankyo is a leading century-old Japanese pharmaceutical company, having a portfolio of proprietary drugs. With Sales of \$8bn, the company is ranked 22nd in the global pecking order. The company derives majority of its revenues from the Regulated markets with Japan being the key market. On the R&D front, the company focuses on the six areas of cardiovascular diseases, glucose metabolic disorders, infectious diseases, cancer, immunity and allergies, and bones/joint diseases. The company spent around 18.6% of Sales on R&D (in FY2007). Currently, it has a pipeline of around 10 molecules in Phase III. Thus, with this acquisition, the company would get access to the proprietary drug portfolio of Daiichi and catapult Ranbaxy-Daiichi combined to the to 15th largest Pharma company in the world. Further, the fund infusion by Daiichi through the preferential issue and warrants would infuse \$1.2bn in Ranbaxy and enable it to retire its debt. Ranbaxy expects to have cash surplus of around Rs3,000cr, which would further strengthen its balance sheet and business (through both the organic and in-organic routes).
- Management at the helm remains the same:** As per the agreement, the Board will have 10 members, with 4 from Ranbaxy and 6 from Daiichi. Malvinder Singh will continue to be the CEO and MD and will also become a member of the senior global management of Daiichi.

- **Daiichi Sankyo to gain from the global spread of Ranbaxy:** Acquisition of Ranbaxy would provide Daiichi Sankyo a presence in high-growth Emerging markets like India, China and Eastern Europe. Further, with Ranbaxy being present in more than 40 countries provides a strong front for Daiichi Sankyo to launch its products. Along with providing a front-end, the deal also provides Daiichi a strong generic product portfolio with strong visibility on First-To-File (FTF) product (20 FTF products addressing a market opportunity of \$26bn) launches over the next few years. Large blockbuster drugs will go off patent globally over the next five year span. Ranbaxy is well-positioned to capture the upsides from the same drawing from its product pipeline. In fact, Ranbaxy's FTF product pipeline is the best in the space and captures major upsides from the large blockbuster drugs going off patent in the next few years. Daiichi would leverage Ranbaxy's strengths in the generic markets to strengthen its presence in the emerging generic market in Japan. Apart from the generic markets, Daiichi would also benefit by leveraging the low-cost advantage of the Indian assets both in Manufacturing and R&D. Thus, Daiichi could use Ranbaxy as an out-sourcing hub for its products. However, management has not indicated the potential upsides that could accrue to Ranbaxy on account of the same.
- **Open offer for Zenotech Labs:** Acquisition of the stake in Ranbaxy would entail an open offer for Zentoech in which Ranbaxy holds 46.95%. However, in companies like Krebs Biochem, Jupiter Biosciences and Orchid Chemicals where Ranbaxy's stake is lesser than 20%, an open offer from Daiichi is ruled out.
- **Upsides from the stock limited after the up-move:** After severe underperformance over the last couple of years, the Ranbaxy stock had witnessed a strong run-up in the last one month, rising by more than 40% during the period. We have revised our SOTP Target Price downwards to factor in the Equity dilution in the near term to Rs535 (Rs603). Our Target Price also factors in the strong cash inflows expected following the fund infusion by Daiichi. As per the open offer (Rs737), at the current market price of Rs561 and acceptance ratio of 33% (assuming conversion of the FCCBs and issue of the preferential shares), the Fair Price works out to Rs602, an upside of a mere 7%. **Hence, given the risk–reward ratio, we recommend investors to subscribe to the open offer.**

| Key Financial (Consolidated) | | | | |
|-------------------------------------|----------------|----------------|----------------|----------------|
| YE Dec (Rs cr) | CY2006 | CY2007 | CY2008E | CY2009E |
| Net Sales | 6,012.6 | 6,641.3 | 7,412.8 | 9,163.4 |
| % chg | 17.9 | 10.5 | 11.6 | 23.6 |
| Adj Net Profit | 510.9 | 554.0 | 713.1 | 937.2 |
| % chg | 95.2 | 8.4 | 28.7 | 31.4 |
| FDEPS (Rs) | 10.5 | 11.4 | 14.7 | 19.3 |
| EBITDA Margin (%) | 14.2 | 10.5 | 16.2 | 15.9 |
| P/E (x) | 53.4 | 49.2 | 38.2 | 29.1 |
| RoE (%) | 20.1 | 20.1 | 10.5 | 8.7 |
| RoCE (%) | 16.3 | 16.0 | 13.1 | 11.3 |
| P/BV (x) | 6.3 | 5.4 | 2.1 | 2.0 |
| EV/Sales (x) | 4.1 | 3.7 | 3.2 | 2.6 |
| EV/EBITDA (x) | 28.2 | 23.7 | 19.4 | 16.2 |

Source – Company, Angel Research



Angel Broking Limited

Research Team Tel: 4040 3800
E-mail: research@angeltrade.com
Website: www.angeltrade.com

DISCLAIMER: This document is not for public distribution and has been furnished to you solely for your information and must not be reproduced or redistributed to any other person. Persons into whose possession this document may come are required to observe these restrictions.

Opinion expressed is our current opinion as of the date appearing on this material only. While we endeavor to update on a reasonable basis the information discussed in this material, there may be regulatory, compliance, or other reasons that prevent us from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

The information in this document has been printed on the basis of publicly available information, internal data and other reliable sources believed to be true and are for general guidance only. While every effort is made to ensure the accuracy and completeness of information contained, the company takes no guarantee and assumes no liability for any errors or omissions of the information. No one can use the information as the basis for any claim, demand or cause of action.

Recipients of this material should rely on their own investigations and take their own professional advice. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult their own advisors to determine the merits and risks of such an investment. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions - futures, options and other derivatives as well as non-investment grade securities - involve substantial risks and are not suitable for all investors. Reports based on technical analysis centers on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals.

We do not undertake to advise you as to any change of our views expressed in this document. While we would endeavor to update the information herein on a reasonable basis, Angel Broking, its subsidiaries and associated companies, their directors and employees are under no obligation to update or keep the information current. Also there may be regulatory, compliance, or other reasons that may prevent Angel Broking and affiliates from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

Angel Broking Limited and affiliates, including the analyst who has issued this report, may, on the date of this report, and from time to time, have long or short positions in, and buy or sell the securities of the companies mentioned herein or engage in any other transaction involving such securities and earn brokerage or compensation or act as advisor or have other potential conflict of interest with respect to company/ies mentioned herein or inconsistent with any recommendation and related information and opinions.

Angel Broking Limited and affiliates may seek to provide or have engaged in providing corporate finance, investment banking or other advisory services in a merger or specific transaction to the companies referred to in this report, as on the date of this report or in the past.

Sebi Registration No : INB 010996539

Ratings (Returns) : Buy (Upside > 15%)
Reduce (Downside upto 15%)

Accumulate (Upside upto 15%)
Sell (Downside > 15%)

Neutral (5 to -5%)